Loading
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Latest quote
$1.86
$0.00 · 0.00%
After-hours
$1.86
$0.00 · 0.00%
Sep 14, 7:49 PM ET
Regular session · ET · Market data may be delayed.
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Day range
Current $1.86
52-week range
Current $1.86
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
49
Fair Value
Sentiment
61
Bullish
Risk
60
Elevated Risk
Momentum
43
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Day range
Current $1.86
52-week range
Current $1.86
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 15.28M EUR | 18.91M EUR | 6.51M EUR | 3.59M EUR | 1.34M EUR |
| Cost of goods sold | 2.6M EUR | — | — | — | — |
| Gross profit | 12.68M EUR | 18.91M EUR | 6.51M EUR | 3.59M EUR | 1.34M EUR |
| Research and development | 40.72M EUR | 36.36M EUR | 25.15M EUR | 50.87M EUR | 42.22M EUR |
| Selling, general, and administrative | 15.06M EUR | 13.66M EUR | 16.24M EUR | 18.65M EUR | 17.37M EUR |
| Operating expenses | 54.84M EUR | 49.38M EUR | 38.37M EUR | 68.75M EUR | 58.55M EUR |
| Interest income | 2.24M EUR | 3.25M EUR | 2.59M EUR | 106K EUR | 5K EUR |
| Interest expense | 866.4K EUR | 1.08M EUR | 1.2M EUR | 5.13M EUR | 3.41M EUR |
| Depreciation and amortization | 2.6M EUR | 2.76M EUR | 2.51M EUR | 2.52M EUR | 2.33M EUR |
| Operating income | −42.15M EUR | −30.47M EUR | −31.86M EUR | −65.16M EUR | −57.21M EUR |
| Net income | −40.52M EUR | −27.76M EUR | −28.12M EUR | −64.42M EUR | −60.74M EUR |
Company facts updated Sep 15, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$3.00
61.29% upsidePrice history unavailable
High $3.00Average $3.00Low $3.00AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
